Is serum β2-microglobulin a tumor marker in gastrointestinal cancer?

Staab, Hans-Jurgen; Anderer, F. A.; Hiesche, K.; Wehrle, Elisabeth; Rodatz, Wolfram

doi:10.1016/0009-8981(80)90315-0

Cited by 11 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the CEA follow-up showed only 3/82 (4%) false negative indications. These results correspond to the data of a previous study carried out with patients with carcinomas of the gastrointestinal tract (42).…”

Section: Discussionsupporting

confidence: 91%

Comparison of Serum β2-Microglobulin and Carcinoembryonic Antigen (CEA) in the Follow-Up of Breast Cancer Patients

Staab¹,

Ahlemann²,

Anderer³

et al. 1981

CCLM

View full text Add to dashboard Cite

Staab, Ahlemann, Anderer, Hiesche and Rodatz: Serum 02-microglobulin and carcinoembryonic antigen in breast cancer pat icnts 339 J. Clin. Chem. Clin. Biochem. Vol. 19, 1981, pp. 339-345 Summary: Using commercially available radioimmune test kits, serial determinations of serum j32-microglobulin and CEA were performed in 337 patients, who had been treated for breast cancer by modified radical mastectomy and radiotherapy. The pre-therapeutic data indicated a higher incidence of pathological j32-microglobulin and CEA levels in patients with distant metastases than in patients with localized disease. However, this finding did not allow the conclusion of a direct complementarity of j32-microglobulin and CEA as tumour markers, since the group of patients with distant metastasis contained a high percentage of elderly patients who generally can be expected to have elevated 02-microglobulin serum concentrations. Therefore, the correlation of the clinical course of malignant disease and the incidence of relapses with the changes of serum |32-microglobulin and CEA concentrations was examined during the posMreatment surveillance: 7/9 cases (78%) with local recurrence and 46/73 cases (63%) with distant spread of disease were not indicated in the |32-microglobulin follow-up by pathologic serum concentrations, whereas in the CEA follow-up only 1/9 and 2/73 false negative indications were registered. The poor correlation suggests that serum 02-microglobulin is not directly tumour associated in breast cancer and does not fulfill the criteria of a tumour marker. Comparison of Serum ß2-Microglobulin and Carcinoembryonic Antigen (CEA) in the Follow-Up of Breast Cancer Patients Vergleich von Serum ß2?Mikroglobulin und CEA in der klinischen Überwachung von Patienten mit Brustkrebs

show abstract

Section: Discussionsupporting

confidence: 91%

Comparison of Serum β2-Microglobulin and Carcinoembryonic Antigen (CEA) in the Follow-Up of Breast Cancer Patients

Staab¹,

Ahlemann²,

Anderer³

et al. 1981

CCLM

View full text Add to dashboard Cite

show abstract

“…Multiple lines of evidence show that β2-m is involved in cancer and other human malignancies. Increased synthesis and release of β2-m, as indicated by elevated serum, plasma, or urine β2-m concentration, occurs in several malignant diseases, including prostate cancer, lung cancer, breast cancer, renal cell carcinoma (RCC), gastrointestinal and nasopharyngeal cancers, hepatocellular carcinoma, ovarian cancer, multiple myeloma, and lymphocytic malignancies such as non-Hodgkin’s lymphoma, in addition to autoimmune and chronic infectious diseases [19, 21-29, 49, 50]. Furthermore, a number of studies have demonstrated that the level of serum β2-m is one of the most important independent prognostic factors and survival predictors for some tumors including RCC, multiple myeloma, and T-cell leukemia [22, 24, 28].…”

Section: β2-m As a Biomarker For Cancersmentioning

confidence: 99%

β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy

Nomura¹,

Huang²,

Zhau³

et al. 2014

ACAMC

View full text Add to dashboard Cite

β2-microglobulin (β2-m) has become the focus of intense scrutiny since the discovery of its undesirable roles promoting osteomimicry and cancer progression. β2-m is a well-known housekeeping protein that forms complexes with the heavy chain of major histocompatibility complex class I molecules, which are heterodimeric cell surface proteins that present antigenic peptides to cytotoxic T cells. On recognition of foreign peptide antigens on cell surfaces, T cells actively bind and lyse antigen-presenting cancer cells. In addition to its roles in tumor immunity, β2-m has two different functions in cancer cells, either tumor promoting or tumor suppressing, in cancer cell context-dependent manner. Our studies have demonstrated that β2-m is involved extensively in the functional regulation of growth, survival, apoptosis, and even metastasis of cancer cells. We found that β2-m is a soluble growth factor and a pleiotropic signaling molecule which interacts with its receptor, hemochromatosis protein, to modulate epithelial-to-mesenchymal transition (EMT) through iron-responsive pathways. Specific antibodies against β2-m have remarkable tumoricidal activity in cancer, through β2-m action on iron flux, alterations of intracellular reactive oxygen species, DNA damage and repair enzyme activities, β-catenin activation and cadherin switching, and tumor responsiveness to hypoxia. These novel functions of β2-m and β2-m signaling may be common to several solid tumors including human lung, breast, renal, and prostate cancers. Our experimental results could lead to the development of a novel class of antibody-based pharmaceutical agents for cancer growth control. In this review, we briefly summarize the recent data regarding β2-m as a promising new cancer therapeutic target and discuss antagonizing this therapeutic target with antibody therapy for the treatment of localized and disseminated cancers.

show abstract

“…In humans, also known as component of the cells associated with the heavy chains of major histocompatibility complex (MHC) class I molecules, the β 2 -microglobulin polypeptide is encoded by the B2M gene [1,2]. β2M levels are elevated in many tumors, including small cell lung cancer, T cell leukemia, breast cancer, renal cell carcinoma (RCC), prostate cancer, gastrointestinal cancers, hepatocellular carcinoma, ovarian cancer, multiple myeloma, and lymphocytic malignancies such as non-Hodgkin's lymphoma [3][4][5][6][7][8][9][10][11]. It also associated with an enhanced rate of cell production or disruption, viral infections such as cytomegalovirus (CMV), and some conditions that activate the immune system, such as autoimmune disorders and inflammatory conditions.…”

Section: Introductionmentioning

confidence: 99%

Dickkopf-3 (DKK-3) obstructs VEGFR-2/Akt/mTOR signaling cascade by interacting of β2-microglobulin (β2M) in ovarian tumorigenesis

Kim

Lee

Seo

et al. 2015

Cellular Signalling

View full text Add to dashboard Cite

Is serum β2-microglobulin a tumor marker in gastrointestinal cancer?

Cited by 11 publications

References 13 publications

Comparison of Serum β2-Microglobulin and Carcinoembryonic Antigen (CEA) in the Follow-Up of Breast Cancer Patients

Comparison of Serum β2-Microglobulin and Carcinoembryonic Antigen (CEA) in the Follow-Up of Breast Cancer Patients

β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy

Dickkopf-3 (DKK-3) obstructs VEGFR-2/Akt/mTOR signaling cascade by interacting of β2-microglobulin (β2M) in ovarian tumorigenesis

Contact Info

Product

Resources

About

Is serum β2-microglobulin a tumor marker in gastrointestinal cancer?

Cited by 11 publications

References 13 publications

Comparison of Serum β2-Microglobulin and Carcinoembryonic Antigen (CEA) in the Follow-Up of Breast Cancer Patients

Comparison of Serum β2-Microglobulin and Carcinoembryonic Antigen (CEA) in the Follow-Up of Breast Cancer Patients

&#946;2-Microglobulin-mediated Signaling as a Target for Cancer Therapy

Dickkopf-3 (DKK-3) obstructs VEGFR-2/Akt/mTOR signaling cascade by interacting of β2-microglobulin (β2M) in ovarian tumorigenesis

Contact Info

Product

Resources

About

β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy